A Literature Review of Immunotherapeutics in the Management of Adult B-Cell Acute Lymphoblastic Leukemia Authors: Tamer Othman, Ibrahim Aldoss Published: 2026 ABSTRACT AbstractRelapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) has historically been associated with poor outcomes in adults treated with conventional chemotherapy. Allogeneic hematopoietic cell transplantation (HCT) in second remission has been the only strategy associated with durable remissions and potential cure. However, achieving remission after first relapse was challenging in the era predating immunotherapy, and remissions were often brief, frequently limiting the ability to proceed to HCT. Consequently, for decades there has been a critical need for more effective therapeutic approaches in R/R B-ALL. Fortunately, in the last decade, B-ALL has undergone a remarkable therapeutic transformation with the introduction of novel targeted immunotherapies. Blinatumomab, inotuzumab ozogamicin, and chimeric antigen receptor (CAR) T-cell therapy have substantially improved patient outcomes in the R/R disease settings while reducing reliance on intensive cytotoxic chemotherapy, and their use has increasingly expanded into the frontline setting as well. This literature review summarizes the pivotal clinical trials supporting the use of blinatumomab, inotuzumab ozogamicin, and CAR T-cell therapies in B-ALL, with a particular focus on their efficacy and toxicity profiles. We also provide our perspective on how these agents can be incorporated into clinical practice and highlight emerging therapeutic agents and strategies. In conclusion, continued advancement and earlier integration of immunotherapeutic approaches could improve long-term outcomes in patients with B-ALL.Keywords: B-cell acute lymphoblastic leukemia, B-ALL, blinatumomab, chimeric antigen receptor T-cells, CAR T, inotuzumab Introduction Relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) has long been associated with poor outcomes in adults.1,2 ALL is a rare malignancy, with approximately 6800 new cases diagnosed annually in the United States, and historically, long-term survival rates in adults ranged between 40–50%.3 Historically, the treatment of adult B-ALL relied on multiagent chemotherapy, with pediatric-inspired regimens commonly used in younger adults and hyper-CVAD-based regimens frequently used across a broader adult population.3 However, traditional combination chemotherapy in first relapse led to complete remission (CR) rates of 30–50% and 5-year overall survival (OS) rates <10%.4 Moreover, no salvage chemotherapy regimen was ever standardized, and allogeneic hematopoietic cell transplantation (HCT) in second remission was the best approach to achieve durable remissions and potential cure.5 However, low remission rates after first relapse, along with the short duration of remission among patients who attained CR, represented major challenges that often limited the feasibility of HCT.6 Moreover, toxicity rates were high. These limitations created a critical need for more effective and less toxic therapies capable of achieving deeper remissions, increasing access to curative HCT, and ultimately improving long-term survival. The armamentarium for managing R/R B-ALL has expanded in the past decade with the introduction of novel immunotherapeutic agents. These include antibody-based therapies, such as the CD19-targeting bispecific T-cell engager (BiTE) blinatumomab, the CD22-targeting antibody drug conjugate (ADC) inotuzumab ozogamicin, and CD19-targeting chimeric antigen receptor (CAR) T-cell therapies.3,4,7–11 Blinatumomab and inotuzumab produced superior outcomes compared with salvage chemotherapy and enabled a higher proportion of patients to undergo HCT, leading to their initial approval by the US Food and Drug Administration (FDA) and other regulatory agencies worldwide.12–14 Subsequently, three CAR T-cell therapies were approved in R/R B-ALL based on single-arm Phase 2 trials that demonstrated high CR rates and durable remissions.15–18 Use of these novel agents has improved the outcomes of R/R B-ALL and has become integral to its management.19 With the advent of these immunotherapeutic agents, 4-year survival rates have improved to 80–85% in B-ALL.4 In this review, we summarize the landmark efficacy and toxicity data for novel immunotherapeutic agents in B-ALL, discuss their clinical applications, and highlight their respective advantages and limitations. Although this review focuses primarily on adult B-ALL, selected pediatric and adolescent/young adult studies are discussed when they established the clinical development of therapies now used in adults or provide important insights relevant to adult practice. We also address persistent unmet clinical challenges, including the inability to achieve durable remissions in many patients and the poor long-term outcomes following relapse after immunotherapy, particularly in those with antigen loss. We also provide insights into future directions and emerging therapeutic agents currently under investigation. Blinatumomab Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that simultaneously binds to both CD19 on B-cells and CD3 on T-cells, thereby activating native T cells by linking them to B-ALL cells.20 This results in a cascade of events starting with the formation of a cytolytic synapse, increased expression of cell adhesion molecules, cytolytic proteins (perforin, granzymes) production, release of inflammatory cytokines, and increased T-cell proliferation, all of which lead to a redirected lysis of CD19-positive B-ALL cells.21 The clinical development of blinatumomab has progressed from treatment of R/R B-ALL to measurable residual disease (MRD)-positive disease and, more recently, to frontline consolidation. Accordingly, the pivotal clinical trials discussed below illustrate the progressive expansion of blinatumomab across these disease settings and ultimately established its role as a standard component of modern adult B-ALL therapy.22 Blinatumomab first showed anti-leukemic activity in R/R B-ALL in an exploratory dose-finding and phase 2 studies.23–25 In a pivotal, multicenter, phase 2 trial, blinatumomab produced a CR/complete response with partial hematologic recovery (CRh) of 43%, and a median OS of 6.1 months. In the confirmatory Phase 3 TOWER trial, adults with R/R Philadelphia chromosome-negative (Ph-) B-ALL were randomized 2:1 to blinatumomab vs. standard chemotherapy.12 Blinatumomab led to higher CR rates (34% vs 16%; p<0.001) with MRD- rates of 76% vs 48%, superior 6-month EFS (31% vs 12%; HR 0.55; p<0.001) and longer median OS of 7.7 vs 4.0 months (HR 0.71; p=0.012). A limitation of the TOWER trial was the exclusion of Philadelphia chromosome-positive (Ph+) B-ALL patients. After the success observed with blinatumomab in the R/R setting, subsequent trials aimed to introduce it earlier in the treatment course for B-ALL. The BLAST enrolled adult patients with persistent or recurrent MRD ≥10−3 while in CR1 or CR2 after at least 3 blocks of intensive chemotherapy.26,27 The MRD-negativity rate (<10−4) was 78%, and blinatumomab facilitated HCT in 76 patients (66%). The median OS was 36.5 months. These results led to the FDA approval of blinatumomab for MRD-positive CR1 or CR2. Shortly after, a single-arm, Phase II study from MD Anderson Cancer Center (MDACC) confirmed these findings in adults with B-ALL with an even lower MRD threshold (≥10−4) after ≥3 months from first-line therapy initiation or one month from the start of any salvage therapy.28 The MRD-negative conversion rate was 73%, and the 3-year RFS and OS was 63% and 67%, respectively, further implying benefit from earlier blinatumomab use. Following these trials, the ECOG 1910 study was conducted, which was the landmark trial prompting approval for blinatumomab use in frontline consolidation.29,30 Adults aged 30–70 with newly diagnosed Ph- B-ALL in MRD-negative CR1 were randomized to receive consolidation chemotherapy with or without chemotherapy after induction. The addition of blinatumomab significantly improved OS in patients with MRD-negative CR1 (HR 0.42; p=0.003), with a 3-year OS of 85% compared to 68% in those who did not receive blinatumomab. A subgroup analysis showed that this benefit was most pronounced in patients <55 years, with a 3-year OS 95% vs 70%; HR 0.16, while such benefit was not observed in older patients. Nonetheless, it is important to note that the study was not powered to evaluate the benefit of blinatumomab within age-defined groups. The phase 2 B-QUEST trial also incorporated blinatumomab in consolidation in CR1, but focused on high-risk Ph- B-ALL as defined by the GRAALL-2005 study, namely KMT2A rearrangements, IKZF1 deletion, or MRD ≥10−4 at the end of induction.31,32 Ninety-four patients were enrolled, and compared to a historical cohort of 90 patients from the GRAALL-2014 trial who did not receive blinatumomab during consolidation before B-QUEST activation. Blinatumomab improved MRD clearance, 72% vs 55% (p=0.04), reduced cumulative incidence of relapse (CIR), 23% vs 49% (p=0.001), and improved 5-year disease-free survival (DFS) and OS, 68% vs 42% (p=0.001) and 79% vs 60% (p=0.03). In a subgroup analyses, the addition of blinatumomab was associated with improved CIR and DFS among patients with IKZF1 deletion and MRD ≥10−4 post-induction, however, this benefit was not observed in patients with KMT2A rearrangement. Of note, HCT did not appear to improve DFS in prior blinatumomab recipients, HR 0.76 (95% CI 0.39–1.50). Finally, consolidative blinatumomab in CR1 has been incorporated in other regimens, such as hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone), which produced a 3-year RFS and OS of 73%.33 Finally, a single-center retrospective study demonstrated the feasibility of incorporating consolidative blinatumomab into the CALGB 10403 regimen, with median overall survival not reached after a median follow-up of 13.7 months.34 Blinatumomab has also improved outcomes in Ph+ B-ALL, which was initially demonstrated in the ALCANTRA trial, a phase 2 trial that enrolled R/R Ph+ B-ALL who failed at least 1 second generation TKI.35,36 The observed CR/CRh rate was 35.6%, including 4 out of 10 patients with a T315I mutation, and an MRD-negativity rate of 88% (BCR::ABL1 PCR <10−4). The median relapse-free survival (RFS) and OS were 6.8 months and 9.0 months, respectively. Following up on these results, the D-ALBA phase 2 trial (GIMEMA LAL2116) enrolled adults with newly diagnosed Ph+ B-ALL to receive dasatinib induction followed by blinatumomab consolidation.37,38 Molecular response, defined as BCR::ABL1/ABL1 = 0 or positive unquantifiable BCR::ABL1,39 increased from 29% after dasatinib to 60% after 2 cycles of blinatumomab consolidation. Long-term follow-up showed a DFS and OS of 75.8% and 80.7%, respectively at 53 months, without chemotherapy or HCT in approximately half of the patients. Notably, patients with an IKZF1plus genomic signature had worse outcomes. MDACC conducted a similar trial but with ponatinib as the TKI and blinatumomab was administered during the first cycle of induction.40–42 After a median follow-up of 24 months, the complete molecular response (CMR) rate was 83%, and the rate of MRD-negativity by immunoglobulin/T-cell receptor clonotyping by next-generation sequencing (Ig/TCR NGS) was 98%. Only two patients underwent HCT. The 3-year EFS and OS was 77% and 91%, respectively. On multivariate analysis, the only independent negative prognostic factor was a white blood cell count >75 x 109/L. Finally, the Phase III GIMEMA ALL2820 trial demonstrated the superiority of a chemotherapy-free regimen consisting of a TKI and blinatumomab compared with a TKI plus chemotherapy approach, resulting in higher rates of complete hematologic remission and MRD negativity, fewer deaths, and improved event-free survival.43 With a median follow-up of 19.6 months, the chemotherapy-free strategy achieved a significantly higher 18-month EFS (89.9% vs 76.8%, p=0.011), supporting its adoption as a new standard of care for adults with Ph+ B-ALL. The toxicity profile of blinatumomab is generally consistent across settings. The first is cytokine release syndrome (CRS), typically grade <3 and occurs ~5-13% of patients, although the incidence and severity of toxicity increases with higher leukemic burden at the time of initiation.44 The second is neurotoxicity, manifesting as confusion, tremor, and seizures. Grade ≥3 occurs in approximately in ~3-10%. These adverse events are generally reversible with dose interruption and/or corticosteroids, although sometimes drug discontinuation may be warranted. When compared with chemotherapy comparator arms in randomized trials, blinatumomab consistently demonstrated lower rates of mucositis, neutropenic fever, and infection, which can be especially advantageous particularly in elderly patients and those less fit for intensive therapy.12,30,37 Of note, although infections were an important cause of serious adverse events in the ECOG 1910 and the AALL1731 trials, no major infectious safety signal emerged that offset the substantial survival benefit observed with blinatumomab.30,45 Table 1 summarizes the landmark trials for blinatumomab, including efficacy and toxicity outcomes. Table 1Key Blinatumomab TrialsTrialPhasePopulationNEfficacy OutcomesNotable ToxicitiesReferencesTOWER3R/R Ph- B-ALL271 blinatumomabvs134 chemotherapy CR/CRh/CRi 44% vs 25%6 mo EFS 31% vs 12%mOS 7.7 vs 4.0 mos (p=0.01) Grade ≥3 AEs: 87% (vs 92% chemo)CRS grade ≥3: 5%Neurologic AEs leading to discontinuation: 4%TRM: 16% (mostly infections)[12]BLAST2B-ALL in any CR with MRD ≥10−3116 Complete MRD response: 78%mOS 36.5 mos Grade ≥3 CRS; 1.5%Grade 3–4 neurologic events: 13%No treatment-related deaths reported[26,27]ECOG 1910330–70 yrs, Ph- B-ALL in MRD-negative CR1112 in each arm 3y OS 85% vs 68% (p = 0.003)In age 55 yrs, 3y OS 95% vs 70% Grade ≥3 CRS: 4%Grade ≥3 neurotoxicity: grade ≥3: 23%[30]B-QUEST218–59 yrs, ND Ph- B-ALL with KMT2Ar, IKZF1del, or MRD ≥10−4 following induction94 blinatumomabvs90 historical control 5y relapse 23% vs 49% (p=0.001)5y OS 79% vs 60% (p=0.03)5y DFS 68% vs 42% (p=0.001) CRS not reported - 3% discontinued for grade 3–4 neurotoxicity[31]Hyper-CVAD + Blinatumomab (MDACC)214–59 yrs, ND Ph- B-ALL38 in the initial cohort, 58 (later with addition of inotuzumab) CR 100% with MFC MRD negativity 97%3y RFS 73%3y OS 81% (85% with inotuzumab addition) 1 patient discontinued blinatumomab for grade 2 neurotoxicity[33,46]ALCANTARA2R/R Ph+ B-ALL who failed ≥1 second-gen TK45 CR/CRh 35.6% with 88% MRD responsemRFS 6.8 mosmOS 9.0 mos CRS: 3 patients (all grade 1–2)Grade 3 neurotoxicity: 3 patients, no grade 4–5 neurotoxicity[35,36]D-ALBA (GIMEMA LAL2116)2ND Ph+ ALL63 Molecular response: 29% post-induction to up to 81% after blinatumomab53 mo DFS 75.8%53 mo OS 80.7%, half never received chemotherapy or HCT 21 grade ≥3 AEs total across all patients; 1 transplant-related death (4%)1 grade neurotoxicity reported[37,38]Ponatinib + Blinatumomab (MDACC)2Ph+ ALL (ND R/R and CML-LBP cohorts)55 total, 35 newly diagnosedND cohort: CMR 85%3y EFS 78%3y OS 88%Only 1 patient underwent HCT in CR1 2 patients discontinued ponatinib (1 CVA, 1 DVT)1 discontinued blinatumomab due to neurotoxicityPancreatitis in 2 patients[40,42] Key Blinatumomab Trials CR/CRh/CRi 44% vs 25% CR/CRh/CRi 44% vs 25% 6 mo EFS 31% vs 12% 6 mo EFS 31% vs 12% mOS 7.7 vs 4.0 mos (p=0.01) mOS 7.7 vs 4.0 mos (p=0.01) Grade ≥3 AEs: 87% (vs 92% chemo) Grade ≥3 AEs: 87% (vs 92% chemo) CRS grade ≥3: 5% CRS grade ≥3: 5% Neurologic AEs leading to discontinuation: 4% Neurologic AEs leading to discontinuation: 4% TRM: 16% (mostly infections) TRM: 16% (mostly infections) Complete MRD response: 78% Complete MRD response: 78% mOS 36.5 mos mOS 36.5 mos Grade ≥3 CRS; 1.5% Grade ≥3 CRS; 1.5% Grade 3–4 neurologic events: 13% Grade 3–4 neurologic events: 13% No treatment-related deaths reported No treatment-related deaths reported 3y OS 85% vs 68% (p = 0.003) 3y OS 85% vs 68% (p = 0.003) In age 55 yrs, 3y OS 95% vs 70% In age 55 yrs, 3y OS 95% vs 70% Grade ≥3 CRS: 4% Grade ≥3 CRS: 4% Grade ≥3 neurotoxicity: grade ≥3: 23% Grade ≥3 neurotoxicity: grade ≥3: 23% 5y relapse 23% vs 49% (p=0.001) 5y relapse 23% vs 49% (p=0.001) 5y OS 79% vs 60% (p=0.03) 5y OS 79% vs 60% (p=0.03) 5y DFS 68% vs 42% (p=0.001) 5y DFS 68% vs 42% (p=0.001) CRS not reported CRS not reported - 3% discontinued for grade 3–4 neurotoxicity - 3% discontinued for grade 3–4 neurotoxicity CR 100% with MFC MRD negativity 97% CR 100% with MFC MRD negativity 97% 3y RFS 73% 3y RFS 73% 3y OS 81% (85% with inotuzumab addition) 3y OS 81% (85% with inotuzumab addition) 1 patient discontinued blinatumomab for grade 2 neurotoxicity 1 patient discontinued blinatumomab for grade 2 neurotoxicity CR/CRh 35.6% with 88% MRD response CR/CRh 35.6% with 88% MRD response mRFS 6.8 mos mRFS 6.8 mos mOS 9.0 mos mOS 9.0 mos CRS: 3 patients (all grade 1–2) CRS: 3 patients (all grade 1–2) Grade 3 neurotoxicity: 3 patients, no grade 4–5 neurotoxicity Grade 3 neurotoxicity: 3 patients, no grade 4–5 neurotoxicity Molecular response: 29% post-induction to up to 81% after blinatumomab Molecular response: 29% post-induction to up to 81% after blinatumomab 53 mo DFS 75.8% 53 mo DFS 75.8% 53 mo OS 80.7%, half never received chemotherapy or HCT 53 mo OS 80.7%, half never received chemotherapy or HCT 21 grade ≥3 AEs total across all patients; 1 transplant-related death (4%) 21 grade ≥3 AEs total across all patients; 1 transplant-related death (4%) 1 grade neurotoxicity reported 1 grade neurotoxicity reported CMR 85% CMR 85% 3y EFS 78% 3y EFS 78% 3y OS 88% 3y OS 88% Only 1 patient underwent HCT in CR1 Only 1 patient underwent HCT in CR1 2 patients discontinued ponatinib (1 CVA, 1 DVT) 2 patients discontinued ponatinib (1 CVA, 1 DVT) 1 discontinued blinatumomab due to neurotoxicity 1 discontinued blinatumomab due to neurotoxicity Pancreatitis in 2 patients Pancreatitis in 2 patients Inotuzumab Inotuzumab ozogamicin is a CD22-targeted ADC composed of a humanized anti-CD22 monoclonal antibody linked covalently to N-acetyl-γ-calicheamicin, a highly potent cytotoxic compound that causes double-stranded DNA breaks and triggers apoptosis.47 After binding to CD22, which is expressed on more than 90% of B-ALL cells, the ADC-CD22 complex is rapidly internalized. The linker is then cleaved through hydrolysis, releasing calicheamicin inside the cell. Clinical development of inotuzumab ozogamicin initially focused on R/R CD22-positive B-ALL, where randomized studies established its superiority over conventional salvage chemotherapy. Subsequent investigations evaluated its incorporation into reduced-intensity frontline regimens, chemotherapy-free approaches for older adults, and MRD-directed therapy, substantially expanding its clinical applications.9,48 Inotuzumab ozogamicin first demonstrated clinical activity with a response rate of 58% and less sinusoidal obstructive syndrome (SOS) with a weekly dose compared to higher doses every 3–4 weeks.49 This led to the phase 3 INO-VATE trial, where adults with R/R B-ALL were randomized to inotuzumab vs standard intensive chemotherapy.13 A total of 326 patients were enrolled. In the primary intention-to-treat analysis of the first 218 patients, the CR/CRi was 80.7% vs 29.4% (p<0.001), with an MRD-negativity rate of 78.4% vs 28.1% (p<0.001). The median PFS and OS was 5.0 vs 1.8 months (p<0.001), and 7.7 vs 6.7 months (p=0.04), respectively. The final report with over 2 years follow-up confirmed a 2-year OS of 22.8% vs 10.0% (p=0.01), and higher HCT utilization (39.6% vs 10.5%; p<0.0001). Among the 49 Ph+ B-ALL patients, inotuzumab ozogamicin achieved higher rates of CR/CRi (73% vs 56%) and MRD-negativity (81% vs 33%) and transition to HCT (41% vs 19%). There was no OS benefit however, with a median of 8.7 vs 8.4 months, although this may be due to the small sample size and higher use of ponatinib in the control arm.50 Mini-hyper-CVD + inotuzumab ozogoamicin with or without blinatumomab was studied at MDACC in phase 2 trial. Among 110 patients with R/R Ph- B-ALL, the overall response rate and CR rates were 83% and 63%, respectively, with an MRD-negativity rate of 82%.51–53 After a median follow-up of 48 months, the median and 3-year OS were 17 months and 40%, respectively, higher than the rates observed with single agent blinatumomab and inotuzumab ozogamicin. In patients ≥60 years old with newly diagnosed Ph- B-ALL, this regimen produced an ORR and CR rate of 99% and 90%, respectively, with an MRD-negativity rate of 94%.54–56 After a median follow-up of 65 months, the 5-year continuous remission and OS rate was 78% and 48%, respectively. Outcomes were favorable in patients aged 60–69 without poor-risk cytogenetics, 5-year OS 72%. A separate propensity score-matched that compared this regimen against hyper-CVAD showed superior 3-year EFS, 64% vs 34% (p=0.003) and OS, 63% vs 34% (p=0.004). The combination of hyper-CVAD followed by blinatumomab with or without inotuzumab ozogamicin in patients under the age of 60 years with newly diagnosed Ph- B-ALL was also evaluated in a phase 2 study at MDACC with 4-year relapse-free survival and overall survival rates of 78% and 87%, respectively.57 Outcomes appeared particularly favorable in patients who additionally received inotuzumab ozogamicin, 3-year RFS and OS of 90% vs 74% (p=0.06) and 100% vs 82% (p=0.01), respectively. The INITIAL-1 phase 2 trial also studied inotuzumab ozogamicin in the frontline setting and enrolled 45 patients over the age of 55 years with Ph- B-ALL.58 Patients were treated with inotuzumab plus dexamethasone induction, followed by age-adapted GMALL consolidation. The CR/CRi rate was 100%, and the MRD-negativity rate was 71%. After a median follow-up of 2.7 years, the 1-year EFS and 3-year OS were 88% and 73%, respectively. The Alliance A041703 phase 2 trial explored a chemotherapy-free sequential regimen of inotuzumab ozogamicin followed by blinatumomab in newly diagnosed Ph- B-ALL.59 Thirty-three patients ≥60 years were enrolled. The composite CR rate was 85% after inotuzumab and 97% by end of blinatumomab. After a median follow-up of 30 months, the 1-year EFS and OS were 75% and 85%, respectively. Additionally, inotuzumab ozogamicin was studied as an MRD eradicator in a phase 2 study by MDACC.60 Twenty-seven patients with B-ALL in CR but had detectable MRD ≥0.01% received low-dose inotuzumab ozogamicin, and 67% achieved MRD negativity (80% of Ph- B-ALL and 59% of Ph+ B-ALL). After a median follow-up of 21 months, 72% remained MRD-negative, and the 2-year EFS and OS were 61% and 62%, respectively. Finally, incorporation of inotuzumab ozogamicin into the pediatric-inspired CALGB 10403 regimen in the phase 3 Alliance A041501 trial.61 In this trial, patients were randomized to receive inotuzumab as part of consolidation or to continue with the original CALGB 10403 protocol.62 The 3-year EFS and OS were similar between the 2 groups, 69.0% vs 66.7% and 79.4% vs 80.3% with inotuzumab ozogamicin vs the control, respectively. Of note, a higher incidence of grade 5 adverse events, including infection-related deaths, was observed following randomization in the inotuzumab ozogamicin arm. The primary toxicity of inotuzumab ozogamicin is hepatotoxicity including SOS, which is the main dose-limiting concern. Risk factors include prior or subsequent HCT (particularly with dual alkylator conditioning), elevated bilirubin, and higher cumulative inotuzumab doses. The transition from bolus dosing (1.3–1.8 mg/m2) to weekly fractionated dosing (0.5–0.8 mg/m2 per dose), dose capping, ursodiol prophylaxis, and avoiding dual alkylator conditioning has reduced SOS rates from ~23% to 2–4% without compromising antileukemic activity. Table 2 summarizes the clinical efficacy and toxicity data of the pertinent trials for inotuzumab ozogamicin. Table 2Key Inotuzumab Ozogamicin TrialsTrialPhasePopulationNEfficacy OutcomesNotable ToxicitiesReferencesINO-VATE3R/R B-ALL (1st or 2nd salvage)164 inotuzumab vs 162 chemotherapy CR/CRi 73.8% vs 30.9% (p<0.001)MRD-neg 78.4% vs 28.1% (p<0.001)mOS 7.7 vs 6.2 mos (p=0.01)2y OS 22.8% vs 10.0%mPFS 5.0 vs 1.8 moSOS: 14.0% vs 2.1%[13]INO-VATE Ph+ subgroup3 (subgroup)R/R Ph+ B-ALL22 inotuzumab vs 27 chemotherapy CR/CRi 73% vs 56%MRD-neg 81% vs 33%mOS 8.7 vs 8.4 mosno OS benefit)12m PFS 20.1% vs 4.8%SOS: 2 patients (9%) in study 1022, and 2 patients (13%) in study 1010[50]Mini-hyper-CVD + inotuzumab ± blinatumomab (salvage regimen)2R/R Ph- B-ALL110 ORR 83%, CR rate 63%MRD-neg 82%mOS 17 mo3-yr OS 40%SOS reduced from 13% to 2% with modified dosing (p=0.02)[51–53]Mini-hyper-CVD + inotuzumab ± blinatumomab (frontline regimen)2ND Ph- B-ALL, age ≥60y83 CR/CRi 99%MRD-neg 94%5y CR duration 78%5y OS 48%4% SOS with modified dosing, 0% early deaths[54–56]Hyper-CVAD + blinatumomab ± inotuzumab2ND, Ph- B-ALL, age <60y75 CR/CRi 100%MRD-neg by flow 95%MRD-neg by NGS 76%3y RFS 82%, 90% vs 74% with inotuzumab vs without (p=0.06)3y OS 90%, 100% vs 82% with inotuzumab vs without (p=0.01)No SOS[57]INITIAL-12ND Ph- B-ALL, age >55y45 with 43 evaluable CR/CRi 100%MRD-neg 71% after 3 induction cycles3y EFS 55%, 3y OS 73%2% SOSGrade ≥3 AEs primarily hematologic and elevated liver enzymes[58]Alliance A0417032ND Ph- B-ALL age ≥60y33 CR/CRi 85% after inotuzumab, 97% after blinatumomab1y EFS 75%1y OS 85%1 grade 4 SOS (3%)[59]Alliance A0415013ND, Ph- B-ALL, 18–39y273 3y EFS 69.0% vs 66.7%3y OS 79.4% vs 80.3%a higher incidence of grade 5 adverse events, including infection-related deaths and SOS was observed following randomization in the inotuzumab arm.12 grade 5 events after randomization in the inotuzumab arm vs 3 in the control arm Infection/sepsis (n=8)Hepatobiliary in the setting of infection (n=2)Multi-organ failure (n=1)Post-surgical complication (n=1)[61] Key Inotuzumab Ozogamicin Trials CR/CRi 73.8% vs 30.9% (p<0.001) CR/CRi 73.8% vs 30.9% (p<0.001) MRD-neg 78.4% vs 28.1% (p<0.001) MRD-neg 78.4% vs 28.1% (p<0.001) mOS 7.7 vs 6.2 mos (p=0.01) mOS 7.7 vs 6.2 mos (p=0.01) 2y OS 22.8% vs 10.0% 2y OS 22.8% vs 10.0% mPFS 5.0 vs 1.8 mo mPFS 5.0 vs 1.8 mo CR/CRi 73% vs 56% CR/CRi 73% vs 56% MRD-neg 81% vs 33% MRD-neg 81% vs 33% mOS 8.7 vs 8.4 mos mOS 8.7 vs 8.4 mos no OS benefit) no OS benefit) 12m PFS 20.1% vs 4.8% 12m PFS 20.1% vs 4.8% ORR 83%, CR rate 63% ORR 83%, CR rate 63% MRD-neg 82% MRD-neg 82% mOS 17 mo mOS 17 mo 3-yr OS 40% 3-yr OS 40% CR/CRi 99% CR/CRi 99% MRD-neg 94% MRD-neg 94% 5y CR duration 78% 5y CR duration 78% 5y OS 48% 5y OS 48% CR/CRi 100% CR/CRi 100% MRD-neg by flow 95% MRD-neg by flow 95% MRD-neg by NGS 76% MRD-neg by NGS 76% 3y RFS 82%, 90% vs 74% with inotuzumab vs without (p=0.06) 3y RFS 82%, 90% vs 74% with inotuzumab vs without (p=0.06) 3y OS 90%, 100% vs 82% with inotuzumab vs without (p=0.01) 3y OS 90%, 100% vs 82% with inotuzumab vs without (p=0.01) CR/CRi 100% CR/CRi 100% MRD-neg 71% after 3 induction cycles MRD-neg 71% after 3 induction cycles 3y EFS 55%, 3y OS 73% 3y EFS 55%, 3y OS 73% CR/CRi 85% after inotuzumab, 97% after blinatumomab CR/CRi 85% after inotuzumab, 97% after blinatumomab 1y EFS 75% 1y EFS 75% 1y OS 85% 1y OS 85% 3y EFS 69.0% vs 66.7% 3y EFS 69.0% vs 66.7% 3y OS 79.4% vs 80.3%a higher incidence of grade 5 adverse events, including infection-related deaths and SOS was observed following randomization in the inotuzumab arm. 3y OS 79.4% vs 80.3%a higher incidence of grade 5 adverse events, including infection-related deaths and SOS was observed following randomization in the inotuzumab arm. Infection/sepsis (n=8) Infection/sepsis (n=8) Hepatobiliary in the setting of infection (n=2) Hepatobiliary in the setting of infection (n=2) Multi-organ failure (n=1) Multi-organ failure (n=1) Post-surgical complication (n=1) Post-surgical complication (n=1) Car T-Cells The development of CD19-directed CAR T-cell therapy occurred through successive generations of products, beginning with tisagenlecleucel (tisa-cel) in children and young adults, followed by brexucabtagene autoleucel (brexu-cel) and obecabtagene autoleucel (obe-cel) in adults. The pivotal studies below established the efficacy, durability, and toxicity profiles of each product. Tisa-cel was approved based on results from the phase II ELIANA trial, in which 75 patients younger than 26 years with R/R B-ALL received tisa-cel infusion.15 The study demonstrated a CR/CRi rate of 82%, with all responders achieving undetectable MRD. Long-term follow-up showed durable efficacy, with 3-year EFS and OS rates of 42% and 55%, respectively.63 Subsequent real-world studies, including analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) and a consortium of US institutions, validated the efficacy of tisa-cel in children and young adults with R/R B-ALL. Across these studies, CR/CRi rates ranged from 85% to 87%, while 1-year RFS/EFS and OS rates ranged from 50–54% and 64%–72%, respectively.64,65 Unlike ELIANA, which required at least 5% bone marrow blasts for enrollment, nearly half of patients in the US real-world cohort had low disease burden (<5% blasts without CNS-3 or extramedullary disease). Higher disease burden was consistently associated with inferior survival.66–68 Additional studies identified predictors of relapse following tisa-cel therapy. Early loss of B-cell aplasia, suggesting limited CAR T-cell persistence, was associated with increased risk of CD19-positive relapse, whereas high disease burden before lymphodepletion and detectable MRD after CAR T-cell therapy were linked to CD19-negative relapse.69–71 Other studies have demonstrated that sustained MRD negativity by NGS beyond 3 months post-infusion was the strongest predictor of EFS regardless of B-cell recovery, and that MRD positivity at day 28 also correlated with higher relapse risk.72,73 Importantly, tisa-cel showed comparable efficacy across multiple cytogenetic subtypes, suggesting its potential to reduce outcome disparities among leukemia genotypes.74 Brexu-cel also demonstrated promising efficacy in adults with R/R B-ALL in the ZUMA-3 trial.16,17,75 In the phase II study, 55 of 71 enrolled patients received brexu-cel infusion. The median patient age was 40 years, and 42% had previously undergone HCT. The CR/CRi rate was 71%, with 97% of responders achieving MRD negativity. Twenty percent of treated patients subsequently underwent consolidation with HCT. At the 3-year follow-up, median relapse-free survival was approximately 11.6 months regardless of censoring for HCT, and median OS reached 25.6 months without new safety concerns.76 Real-world analyses from the ROCCA consortium and CIBMTR further confirmed the efficacy and safety of brexu-cel in routine clinical practice.77,78 CR/CRi rates ranged from 76% to 90%, while 6-month progression-free/relapse-free survival and OS rates ranged from 53–61% and 78%–81%, respectively. Notably, these outcomes were achieved despite inclusion of patients who may not have met eligibility criteria for ZUMA-3, such as those with symptomatic CNS involvement, underscoring the broader applicability of brexu-cel in adults with R/R B-ALL. Obe-cel is a CD19-directed CAR T-cell therapy incorporating a low-affinity, fast off-rate CD19-binding domain and a 4–1BB co-stimulatory domain.79 This unique construct is designed to create a more physiologic immune synapse, thereby reducing excessive T-cell activation and exhaustion while maintaining antileukemic efficacy. In addition, obe-cel is administered as a split-dose infusion based on disease burden, a strategy intended to mitigate treatment-related toxicities while preserving therapeutic activity. The FELIX trial was a pivotal Phase 1b/2, multicenter, open-label, single-arm study evaluating obe-cel in adults with R/R B-ALL.18 Among 153 enrolled patients, 127 (83%) ultimately received at least one obe-cel infusion. The pivotal efficacy cohort included 94 patients with morphologic disease (≥5% bone marrow blasts), while a separate cohort enrolled patients with MRD. The median age of treated patients was 50 years (range, 20–81), 22% had Ph+ B-ALL, 42% received prior HCT, and the median number of prior lines of therapy was 2. Patients received a target dose of 410 million CAR T-cells administered in a split-dose fashion on days 1 and 10 according to pre-lymphodepletion disease burden. At a median follow-up of 20.3 months, obe-cel demonstrated substantial clinical activity in the pivotal cohort. The CR/CRi was 77%, including a CR rate of 55%. Notably, 97% of responding patients achieved MRD-negativity. The median duration of response was 14.1 months. Across all infused patients, the median EFS and OS were 11.9 months and 15.6 months, respectively, with 12-month EFS and OS rates of 49.5% and 61.1%. Outcomes were strongly influenced by disease burden at the time of lymphodepletion, with median EFS not reached among patients with <5% bone marrow blasts, approximately 15 months among those with 5–75% blasts, and only 5 months among patients with >75% blasts. The 3-year follow-up update demonstrated that 38.4% of responders remained in remission without subsequent therapy without new safety concerns.80 These findings established obe-cel as a highly active product for relapsed/refractory B-ALL, with durable remissions and encouraging survival outcomes in a heavily pretreated patient population. Subsequent post-hoc analyses have shown that lower disease burden at lymphodepletion and ongoing obe-cel persistence at 3 months were associated with superior EFS and OS in patients who remained in remission at that time, including those with NGS MRD-negative remission and no consolidative HCT, compared with loss of obe-cel persistence.81 CRS and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) are the primary toxicities associated with CAR T-cell therapy, although hemophagocytic lymphohistiocytosis (HLH), now termed immune effector cell-associated HLH-like syndrome (IEC-HS) and immune effector cell-associated hematotoxicity (ICAHT) are also well recognized complications.82,83 In the ELIANA trial, tisa-cel led to grade ≥3 CRS and neurotoxicity in 48% and 13% of patients, respectively. In the real-world analyses with tisa-cel, CRS and ICANS were reported less frequently than in ELIANA, occurring in 18–21% and 7–10% of patients, respectively, although different toxicity grading systems were used. In the ZUMA-3 trial, grade ≥3 CRS and neurotoxicity occurred in 24% and 25% of patients, respectively. In the FELIX trial, grade ≥3 CRS and ICANS occurred in only 3% and 8%, respectively. HLH or IEC-HS occurred in 6% (n=5), 4% (n=3), and 2% (n=2) in the ELIANA, ZUMA-3 and FELIX trials, respectively. Table 3 summarizes the efficacy and safety data of the key CAR T-cell trials. Table 3Key CAR T TrialsTrialPhasePopulationNEfficacy OutcomesNotable ToxicitiesReferencesELIANA2R/R B-ALL, ≤25 years old75 CR/CRi 81%MRD-neg 100%3y EFS 42% 3y OS 55% Grade ≥3 CRS: 46%Grade ≥3 ICANS: 14%[15,63]ZUMA-31/2R/R Ph+ B-ALL, ≥18 years old78 (Phase 1+2 at approved dose); 55 (Phase 2 only) CR/CRi 71%MRD-neg 97%mEFS 11.6 mos at 3y follow-upmOS 25.6 mos at 3y follow-up Grade ≥3 CRS: 24–26%Grade ≥3 ICANS: 25–35%[16,17,75,76]FELIX1b/2R/R Ph- B-ALL, ≥18 years old127 CR/CRi 77%MRD-neg 97%2y EFS 43%2y OS 46% Grade ≥3 CRS 2.4%Grade ≥3 ICANS 7.1%[18,80] Key CAR T Trials CR/CRi 81% CR/CRi 81% MRD-neg 100% MRD-neg 100% 3y EFS 42% 3y EFS 42% 3y OS 55% 3y OS 55% Grade ≥3 CRS: 46% Grade ≥3 CRS: 46% Grade ≥3 ICANS: 14% Grade ≥3 ICANS: 14% CR/CRi 71% CR/CRi 71% MRD-neg 97% MRD-neg 97% mEFS 11.6 mos at 3y follow-up mEFS 11.6 mos at 3y follow-up mOS 25.6 mos at 3y follow-up mOS 25.6 mos at 3y follow-up Grade ≥3 CRS: 24–26% Grade ≥3 CRS: 24–26% Grade ≥3 ICANS: 25–35% Grade ≥3 ICANS: 25–35% CR/CRi 77% CR/CRi 77% MRD-neg 97% MRD-neg 97% 2y EFS 43% 2y EFS 43% 2y OS 46% 2y OS 46% Grade ≥3 CRS 2.4% Grade ≥3 CRS 2.4% Grade ≥3 ICANS 7.1% Grade ≥3 ICANS 7.1% How to Use Immunotherapies in B-All Management The incorporation of targeted immunotherapies has fundamentally changed the treatment paradigm for adults with B-ALL. Figure 1 depicts the three immunotherapeutic agents,84 while Table 4 describes their advantages and limitations. In younger, fit adults with newly diagnosed Ph- B-ALL, blinatumomab should now be considered a standard component of frontline therapy irrespective of MRD status following initial induction therapy ± consolidation based on the ECOG 1910 trial and experience with hyperCVAD followed by blinatumomab at MDACC.30,33 At our institution, we incorporate two cycles of blinatumomab after course II of CALGB 10403, one cycle after course III, and one cycle after course IV in young adult patients (18–54 years) with newly diagnosed Ph- B-ALL who achieve MRD-negativity after consolidation.34 For patients who tolerate induction poorly or experience significant toxicities but achieve MRD-negative CR1, we administer the first cycle of blinatumomab immediately after induction. If clinical status improves, patients subsequently resume consolidation therapy with alternating cycles of chemotherapy and blinatumomab. While blinatumomab has improved outcomes across age groups, its benefit may be attenuated among older adults, particularly those over 55 years of age, in whom competing risks, treatment-related toxicity, and adverse disease biology remain important challenges. However, these outcomes observed in older adults may be related to the intensity of the chemotherapy backbone in the ECOG1910. The phase 3 Golden Gate study which randomized older adults to low-intensity chemotherapy alternating with blinatumomab or standard of care chemotherapy my help clarify the role of frontline blinatumomab when administered with low intensity chemotherapy in this patient population.85 For newly diagnosed adult patients with Ph+ ALL, our approach consists of induction with one cycle of low-intensity chemotherapy plus tyrosine kinase inhibitor, preferably ponatinib, based on the PhALLCON study, to cytoreduce the disease burden prior to consolidation. This is followed by a chemotherapy-free regimen consolidation with blinatumomab plus TKI. We also incorporate 1–2 cycles of intermediate-dose systemic methotrexate in patients presenting with extensive extramedullary disease, high white blood cell count, or central nervous system involvement.42,86,87 Current approved immunotherapeutic agents for adult B-ALL. Table 4Advantages and Limits of Each Novel Immunotherapeutic AgentBlinatumomabInotuzumab OzogamicinCAR T-cellsAdvantages Available in CR1 and improves outcomes in this settingHigh activity and durable remission in R/R B-ALL when overall disease burden is lowSafe bridge to HCT and in elderlyAvailable immediately Highly active irrespective of disease burden, genetics, prior HCT, and non-CNS EMD Safe in elderlyCan be combined with chemotherapy Available immediately Highly active irrespective of genetics, prior HCT, presence of CNS disease and EMD Durable remissions and can cure without subsequent therapiesLimitations Not very effective when blasts ≥50% or CNS/non-CNS EMD presentNot curative without subsequent HCTInconvenient for patients as a continuous infusion Not very effective in CNS diseaseNot curative without subsequent HCTIncreases risk of hepatotoxicity and SOS, particularly in those who subsequently receive HCT Manufacturing requires time, and some patients may not receive the product after leukapheresis Higher toxicity rates Less active with high BM blast % or prior blinatumomab failure Advantages and Limits of Each Novel Immunotherapeutic Agent Available in CR1 and improves outcomes in this setting Available in CR1 and improves outcomes in this setting High activity and durable remission in R/R B-ALL when overall disease burden is low High activity and durable remission in R/R B-ALL when overall disease burden is low Safe bridge to HCT and in elderly Safe bridge to HCT and in elderly Available immediately Available immediately Highly active irrespective of disease burden, genetics, prior HCT, and non-CNS EMD Highly active irrespective of disease burden, genetics, prior HCT, and non-CNS EMD Safe in elderly Safe in elderly Can be combined with chemotherapy Can be combined with chemotherapy Available immediately Available immediately Highly active irrespective of genetics, prior HCT, presence of CNS disease and EMD Highly active irrespective of genetics, prior HCT, presence of CNS disease and EMD Durable remissions and can cure without subsequent therapies Durable remissions and can cure without subsequent therapies Not very effective when blasts ≥50% or CNS/non-CNS EMD present Not very effective when blasts ≥50% or CNS/non-CNS EMD present Not curative without subsequent HCT Not curative without subsequent HCT Inconvenient for patients as a continuous infusion Inconvenient for patients as a continuous infusion Not very effective in CNS disease Not very effective in CNS disease Not curative without subsequent HCT Not curative without subsequent HCT Increases risk of hepatotoxicity and SOS, particularly in those who subsequently receive HCT Increases risk of hepatotoxicity and SOS, particularly in those who subsequently receive HCT Manufacturing requires time, and some patients may not receive the product after leukapheresis Manufacturing requires time, and some patients may not receive the product after leukapheresis Higher toxicity rates Higher toxicity rates Less active with high BM blast % or prior blinatumomab failure Less active with high BM blast % or prior blinatumomab failure Another alternative for older adults is chemotherapy-sparing approaches incorporating inotuzumab.55,59 The Alliance A041703 study demonstrated encouraging safety and early efficacy outcomes with induction and consolidation using inotuzumab followed by blinatumomab in older patients with newly diagnosed Ph- B-ALL.88 However, a longer follow up demonstrated the 3-year EFS dropped to 48%. Furthermore, the MDACC experience with mini-hyper-CVD plus inotuzumab subsequently incorporating sequential blinatumomab, has produced durable remissions and favorable survival outcomes while minimizing the toxicity associated with intensive chemotherapy among older adults between the age 60 and 69 years. The increasing availability of highly effective immunotherapies has also created opportunities for risk-adapted treatment strategies. Patients with adverse-risk genomic features, including TP53 mutations, hypodiploidy, complex karyotype, Philadelphia chromosome-like B-ALL, and KMT2A-rearranged disease, continue to experience inferior long-term outcomes despite advances in frontline therapy. In our practice, persistent MRD detected by Ig/TCR NGS following initial chemotherapy identifies a subset of these high-risk patients who may benefit from early consolidative transplant. For patients who are not transplant-eligible, we consider early CD19-directed CAR T-cell therapy as definitive therapy.89 When clinical trials are unavailable, our preferred commercial CAR T product is obe-cel, given its favorable toxicity profile and potential for long-term persistence, which may translate into improved remission durability and curative potential, although long-term follow up is needed to confirm these outcomes.80 Although prospective data supporting this approach remain limited, administering CAR T-cells in CR may maximize efficacy and reduce toxicity. Accordingly, we favor CAR T-cell therapy for persistent MRD in CR1 who are not candidates for or decline HCT. In the R/R setting, as most patients will have already been exposed to blinatumomab in CR1, we favor early use of CAR T-cell therapy in eligible patients with preserved CD19 expression when clinical trials are unavailable, especially in those who relapsed with extramedullary disease or after prior allogeneic HCT. CAR T-cell therapy offers the highest likelihood of achieving deep, MRD-negative remissions and durable disease control, particularly when administered before the development of substantial disease burden or treatment-refractory disease. Prior blinatumomab use should not preclude patients from subsequent CAR T use in patients with R/R disease, as ROCCA data suggests that meaningful responses remain achievable despite prior blinatumomab exposure.90 However, inotuzumab remains an important therapeutic option in patients with CD19-negative relapse and in those requiring rapid cytoreduction who are unable to wait for leukapheresis, manufacturing, and CAR T-cell infusion. In such cases, inotuzumab may serve as a bridging strategy to subsequent cellular therapy such as CAR T or HCT, or as palliative treatment. Since no universally accepted sequencing algorithm currently exists, treatment decisions should be individualized according to disease biology, antigen expression, disease burden, prior therapies, patient fitness, and candidacy for HCT or cellular therapy. Our approach to specific clinical scenarios is summarized in Table 5. Table 5Clinical Considerations for Sequencing Novel Immunotherapeutic Agents in Adult B-Cell Acute Lymphoblastic LeukemiaClinical ScenarioPotential Sequencing ApproachRationale/Key ConsiderationsNewly diagnosed Ph- B-ALL (young, fit)Multi-agent chemotherapy followed by sequential blinatumomab consolidationBased on ECOG1910 and MDACC data demonstrating improved survival with incorporation of blinatumomab in MRD-negative CR1MRD-negative CR1 with poor tolerance of chemotherapyTransition early to blinatumomab, then resume consolidation if clinically appropriateAllows continuation of effective therapy while minimizing additional chemotherapy toxicityNewly diagnosed Ph+ B-ALLLow-intensity chemotherapy + ponatinib induction followed by blinatumomab + TKI consolidationBased on PhALLCON trial and chemotherapy-free TKI/blinatumomab strategies; additional CNS-directed therapy considered for high-risk features.Older adults with Ph- B-ALLReduced-intensity regimens incorporating inotuzumab followed by blinatumomabLower treatment-related toxicity while maintaining durable remissions; supported by Alliance A041703 and MD Anderson studiesHigh-risk genomic features or persistent MRDEarly HCT if eligible; consider CD19 CAR T-cell for transplant-ineligible patients or those declining HCTMRD identifies patients at high risk for relapse despite frontline therapyRelapsed/refractory CD19-positive diseaseEarly CAR T-cell therapy when eligibleHigh likelihood of achieving deep MRD-negative remissionPrior blinatumomab exposureCAR T-cell remains appropriate if CD19 expression is preservedPrior blinatumomab does not preclude meaningful responses to CAR T-cell therapyCD19-negative relapseInotuzumab ozogamicinActive despite CD19 antigen loss; useful for subsequent bridge to HCT or CAR T when appropriateNeed for rapid cytoreduction or CAR T manufacturing delayInotuzumab bridging followed by CAR T-cell therapy or HCTProvides rapid disease control while awaiting definitive cellular therapy Clinical Considerations for Sequencing Novel Immunotherapeutic Agents in Adult B-Cell Acute Lymphoblastic Leukemia Future Directions Despite substantial advances in the treatment of B-ALL, relapse remains a significant challenge, particularly among patients with high-risk disease biology and those who experience antigen-negative escape following targeted therapies. In particular, approximately 10–30% of patients relapse following blinatumomab, and up to 70% relapses following CD19-targeted CAR T-cells are characterized by loss of CD19 expression.91–93 Ongoing efforts are therefore focused on both improving the efficacy of existing immunotherapies and identifying novel therapeutic targets. Surovatamig (AZD0486), a novel CD19×CD3 bispecific antibody with an extended half-life permitting less frequent administration (every 2 weeks as a 2 hours infusion), has demonstrated encouraging activity in heavily pretreated patients with R/R B-ALL, with overall composite CR of 67% across all dose, and including those previously exposed to blinatumomab (55%) and CAR T-cell therapy (65%).94 Early results from the SYRUS study demonstrated high response rates and deep remissions, supporting continued development of this and other novel antibody-based approaches. Additionally, subcutaneous blinatumomab has demonstrated encouraging efficacy and a manageable safety profile in early-phase studies of R/R B-ALL, achieving a high CR/CRh of 77% and MRD-negativity rate of 91% while eliminating the need for continuous intravenous infusion and central venous access.95,96 The ongoing phase 3 AUDAX trial is evaluating whether subcutaneous blinatumomab combined with chemotherapy is non-inferior to standard intravenous blinatumomab in adults with newly diagnosed Ph-negative B-ALL in remission after induction, with the goal of improving efficacy while substantially reducing treatment burden and improving patient convenience. Finally, updated results from the phase 1b/2 study of MK-1045, a novel CD19×CD3 T-cell engager, demonstrated promising single-agent activity in adults with relapsed/refractory B-ALL, with CR/CRi/CRh rates of 83% and 92% at the ≥60 mg and 90 mg dose levels, respectively.97 Responses were deep, with MRD-negativity rates of 89–91%, and encouraging activity was observed even in patients previously treated with blinatumomab or CAR T-cell therapy. Treatment was generally manageable, with predominantly hematologic toxicities, cytokine release syndrome occurring in 45% of patients (grade ≥3, 3%), and no cases of ICANS. Another important area of investigation is the earlier integration of CAR T-cell therapy into the treatment paradigm.98 As previously mentioned, increasing evidence suggests that disease burden at the time of infusion is one of the strongest predictors of long-term outcomes, raising the possibility that CAR T-cell therapy may be most effective when deployed earlier in the disease course before the development of refractory disease and extensive clonal evolution. This concept may be especially relevant for patients with adverse-risk genomic features or persistent MRD after frontline therapy. Several recent phase 1/2 studies have evaluated CAR T-cell therapy as frontline consolidation for adults with newly diagnosed Ph- and Ph+ B-ALL in CR1.98–100 Across these studies, consolidative CAR T-cell therapy produced high rates of sustained MRD-negative remission with encouraging RFS and OS, suggesting that CAR T cells may serve as an effective chemotherapy- and transplant-sparing strategy in selected high-risk patients. Importantly, toxicity was manageable, and these early results support further investigation of CAR T-cell therapy earlier in the treatment course, although longer follow-up and randomized studies are needed to define its role relative to allogeneic transplantation. In parallel, efforts are underway to overcome antigen escape through the development of CAR T-cell therapies directed against alternative targets. Among these, B-cell activating factor receptor (BAFF-R) has emerged as a particularly attractive candidate. In a first-in-human Phase I study, BAFF-R-directed CAR T-cells (PMB-CT01) demonstrated encouraging activity and a favorable safety profile in patients with relapsed/refractory B-ALL, including those with prior CD19-directed therapy exposure and CD19-negative disease.101 Four of six treated patients achieved MRD-negative complete remission, including three patients with CD19-negative disease who subsequently proceeded to allogeneic transplantation; notably, no dose-limiting toxicities or grade ≥3 cytokine release syndrome events were observed. Researchers at City of Hope demonstrated BAFF-R is frequently retained in CD19-negative leukemic cells and developed BAFF-R-directed and dual CD19/BAFF-R CAR T-cell constructs capable of eradicating antigen-heterogeneous B-ALL models while preventing outgrowth of CD19-negative clones.46 These findings provide a strong rationale for clinical evaluation of BAFF-R-targeted cellular therapies as a strategy to address one of the major mechanisms of resistance to current CD19-directed approaches. Beyond novel antigen targets, considerable efforts are focused on developing next-generation cellular therapies designed to improve efficacy, safety, and accessibility.102,103 These include allogeneic (ie, “off-the-shelf”) CAR T-cell products, armored CAR T cells designed to enhance persistence and overcome the immunosuppressive microenvironment, and dual-targeted CAR constructs intended to reduce antigen escape, such as the previously mentioned CD19/BAFF-R CAR T-cell construct. CAR-NK cell therapy has also emerged as a promising alternative platform because of its favorable safety profile, reduced risk of graft-versus-host disease, and potential for scalable allogeneic manufacturing, although limited in vivo persistence and manufacturing challenges remain important obstacles.104 Additionally, combination strategies incorporating immunotherapies with targeted agents, such as tyrosine kinase inhibitors, or other immune-based approaches may further improve response durability while reducing the emergence of resistant disease.105,106 Finally, successful implementation of these therapies will require addressing important real-world challenges, including manufacturing complexity, prolonged production times for autologous products, limited access to specialized cellular therapy centers, and the substantial financial costs associated with treatment.107–109 Advances in rapid manufacturing platforms and off-the-shelf cellular products may help improve accessibility and facilitate broader adoption of these therapies. Conclusion The introduction of blinatumomab, inotuzumab ozogamicin, and CAR T-cell therapies has transformed the treatment landscape of B-ALL, leading to improved outcomes across multiple disease settings (Figure 1 and Table 4). Blinatumomab is now a standard component of frontline therapy, while inotuzumab-based regimens offer highly effective chemotherapy-sparing options for older adults and an important salvage strategy for relapsed disease. CAR T-cell therapy has demonstrated the potential to induce deep, durable remissions and is increasingly being explored earlier in the disease course. Nevertheless, relapse, especially following CD19-directed therapies, remains a significant challenge and underscores the need for continued therapeutic innovation. As the therapeutic landscape continues to evolve, treatment selection should be individualized based on disease biology, MRD status, patient fitness, prior therapies, and access to HCT and cellular therapies. This literature review summarizes the landmark clinical trials that have shaped the use of blinatumomab, inotuzumab ozogamicin, and CAR T-cell therapy in adult B-ALL, and the proposed treatment sequencing reflects an evidence-informed approach based on the available literature and the authors’ clinical experience. Continued advances in cellular therapy, alternative antigen targets such as BAFF-R, and rational sequencing of immunotherapies are expected to further improve outcomes and move the field closer to achieving durable disease control for a greater proportion of patients with B-ALL. Disclosure I.A.—consulting or Advisory Role: Amgen AstraZeneca, Autolus, Jazz Pharmceuticals, Kite/Gilead, Pfizer, Sobi, Syndax, Takeda, Wugen; Honoraria: Amgen; Research Funding: AbbVie, Macrogenics, Novartis. The other authors declare no conflicts of interest. References